Hansa Biopharma AB (HNSAN) Stock Statistics & Valuation Metrics
Total Valuation
Hansa Biopharma AB has a market cap or net worth of MXN 7.66B. The enterprise value is MXN 4.01B.
- Market Cap
- MXN 7.66B
- Enterprise Value
- MXN 4.01B
Share Statistics
Hansa Biopharma AB has 101,763,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 101,763,220
- Owned by Insiders
- ―
- Owned by Institutions
- 3.35%
Financial Efficiency
Hansa Biopharma AB’s return on equity (ROE) is 6.00 and return on invested capital (ROIC) is -57.78%.
- Return on Equity (ROE)
- 6.00
- Return on Assets (ROA)
- -0.46
- Return on Invested Capital (ROIC)
- -57.78%
- Return on Capital Employed (ROCE)
- -0.69
- Revenue Per Employee
- 1.70M
- Profits Per Employee
- -4.08M
- Employee Count
- 131
- Asset Turnover
- 0.19
- Inventory Turnover
- 13.63
Valuation Ratios
The current PE Ratio of Hansa Biopharma AB is -5.01. Hansa Biopharma AB’s PEG ratio is 1.92.
- PE Ratio
- -5.01
- PS Ratio
- 20.71
- PB Ratio
- -7.70
- Price to FCF
- -7.18
- Price to Operating Cash Flow
- -7.59
- PEG Ratio
- 1.92
Income Statement
In the last 12 months, Hansa Biopharma AB had revenue of 222.26M and earned -534.11M in profits. Earnings per share was -6.52.
- Revenue
- 222.26M
- Gross Profit
- 138.71M
- Operating Income
- -520.71M
- Pretax Income
- -531.84M
- Net Income
- -534.11M
- EBITDA
- -483.82M
- Earnings Per Share (EPS)
- -6.52
Cash Flow
In the last 12 months, operating cash flow was -527.70M and capital expenditures -18.54M, giving a free cash flow of -546.24M billion.
- Operating Cash Flow
- -527.70M
- Free Cash Flow
- -546.24M
- Free Cash Flow per Share
- -5.37
Dividends & Yields
Hansa Biopharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -13.92%
- Earnings Yield
- -19.24%
Important Dates
Hansa Biopharma AB upcoming earnings date is Nov 11, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Jul 22, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Hansa Biopharma AB as a current ratio of 1.94, with Debt / Equity ratio of -1049.33%
- Current Ratio
- 1.94
- Quick Ratio
- 1.92
- Debt to Market Cap
- 0.33
- Net Debt to EBITDA
- -0.48
- Interest Coverage Ratio
- -4.43
Taxes
In the past 12 months, Hansa Biopharma AB has paid 2.27M in taxes.
- Income Tax
- 2.27M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Hansa Biopharma AB EV to EBITDA ratio is -7.74, with an EV/FCF ratio of -8.06.
- EV to Sales
- 23.25
- EV to EBITDA
- -7.74
- EV to Free Cash Flow
- -8.06
- EV to Operating Cash Flow
- -8.35
Balance Sheet
Hansa Biopharma AB has MXN 552.81M in cash and marketable securities with MXN 1.03B in debt, giving a net cash position of -MXN 480.99M billion.
- Cash & Marketable Securities
- MXN 552.81M
- Total Debt
- MXN 1.03B
- Net Cash
- -MXN 480.99M
- Net Cash Per Share
- -MXN 4.73
- Tangible Book Value Per Share
- -MXN 7.54
Margins
Gross margin is 57.32%, with operating margin of -310.89%, and net profit margin of -406.50%.
- Gross Margin
- 57.32%
- Operating Margin
- -310.89%
- Pretax Margin
- -405.33%
- Net Profit Margin
- -406.50%
- EBITDA Margin
- -300.44%
- EBIT Margin
- -306.60%
Analyst Forecast
The average price target for Hansa Biopharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -2.89%
- EPS Growth Forecast
- 8.40%
